INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 145 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.94 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,308 | +39.5% | 178,438 | -16.7% | 0.00% | 0.0% |
| Q2 2023 | $2,371 | +51.1% | 214,253 | +83.4% | 0.00% | +100.0% |
| Q1 2023 | $1,569 | -20.7% | 116,826 | -27.0% | 0.00% | 0.0% |
| Q4 2022 | $1,979 | -99.9% | 159,968 | -0.9% | 0.00% | -50.0% |
| Q3 2022 | $2,252,000 | +355.9% | 161,495 | +351.8% | 0.00% | – |
| Q2 2022 | $494,000 | -61.8% | 35,743 | -55.0% | 0.00% | -100.0% |
| Q1 2022 | $1,292,000 | -5.8% | 79,384 | -5.7% | 0.00% | – |
| Q4 2021 | $1,372,000 | +363.5% | 84,158 | +321.4% | 0.00% | – |
| Q3 2021 | $296,000 | -79.4% | 19,969 | -72.2% | 0.00% | -100.0% |
| Q2 2021 | $1,435,000 | -38.4% | 71,874 | -28.7% | 0.00% | 0.0% |
| Q1 2021 | $2,328,000 | +1.2% | 100,866 | +8.3% | 0.00% | 0.0% |
| Q4 2020 | $2,300,000 | -81.4% | 93,137 | -68.8% | 0.00% | -85.7% |
| Q3 2020 | $12,382,000 | +22.3% | 298,613 | +41.4% | 0.01% | -12.5% |
| Q2 2020 | $10,122,000 | -37.3% | 211,246 | -17.6% | 0.01% | -33.3% |
| Q1 2020 | $16,135,000 | +54.6% | 256,273 | +204.4% | 0.01% | +100.0% |
| Q4 2019 | $10,434,000 | +249.0% | 84,199 | +86.8% | 0.01% | +200.0% |
| Q3 2019 | $2,990,000 | -25.6% | 45,063 | -10.8% | 0.00% | 0.0% |
| Q2 2019 | $4,019,000 | -87.8% | 50,503 | -82.8% | 0.00% | -91.3% |
| Q1 2019 | $32,868,000 | +225.2% | 293,838 | +193.0% | 0.02% | +228.6% |
| Q4 2018 | $10,107,000 | -12.1% | 100,285 | +10.2% | 0.01% | -12.5% |
| Q3 2018 | $11,502,000 | +114.5% | 91,017 | +42.4% | 0.01% | +60.0% |
| Q2 2018 | $5,362,000 | +0.4% | 63,916 | -26.4% | 0.01% | +25.0% |
| Q1 2018 | $5,340,000 | -20.3% | 86,809 | -24.3% | 0.00% | -20.0% |
| Q4 2017 | $6,697,000 | +128.8% | 114,655 | +127.4% | 0.01% | +66.7% |
| Q3 2017 | $2,927,000 | -7.6% | 50,430 | +92.6% | 0.00% | -25.0% |
| Q2 2017 | $3,169,000 | -79.7% | 26,185 | -81.0% | 0.00% | -75.0% |
| Q1 2017 | $15,615,000 | +65.8% | 138,074 | +59.3% | 0.02% | +60.0% |
| Q4 2016 | $9,420,000 | +63.1% | 86,698 | +147.1% | 0.01% | +66.7% |
| Q3 2016 | $5,777,000 | -15.5% | 35,089 | -26.8% | 0.01% | -25.0% |
| Q2 2016 | $6,839,000 | +13.2% | 47,924 | +1.5% | 0.01% | -11.1% |
| Q1 2016 | $6,043,000 | +6689.9% | 47,205 | +7887.3% | 0.01% | – |
| Q4 2015 | $89,000 | -92.2% | 591 | -91.4% | 0.00% | -100.0% |
| Q3 2015 | $1,140,000 | +1325.0% | 6,910 | +1981.3% | 0.00% | – |
| Q2 2015 | $80,000 | -97.2% | 332 | -96.8% | 0.00% | -100.0% |
| Q1 2015 | $2,899,000 | -80.3% | 10,281 | -89.1% | 0.00% | -80.0% |
| Q4 2014 | $14,739,000 | +52.7% | 94,489 | +131.1% | 0.02% | +66.7% |
| Q3 2014 | $9,651,000 | -13.9% | 40,895 | -13.9% | 0.01% | -18.2% |
| Q2 2014 | $11,206,000 | -75.8% | 47,480 | -66.3% | 0.01% | -78.8% |
| Q1 2014 | $46,396,000 | +4799.3% | 141,020 | +912.3% | 0.05% | +5100.0% |
| Q4 2013 | $947,000 | +432.0% | 13,931 | +438.3% | 0.00% | – |
| Q3 2013 | $178,000 | +1086.7% | 2,588 | +689.0% | 0.00% | – |
| Q2 2013 | $15,000 | – | 328 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |